Nick Srikanth

Nick Srikanth is the Head of Strategy at Senda Biosciences, where he is responsible for corporate and portfolio strategy, business operations, and external communications. He has a robust background in strategy and consulting, having previously worked at The Boston Consulting Group (BCG), where he advised biopharma clients on various strategic issues including long-term strategy and launch planning.12

Before his current role, Nick held significant positions in the pharmaceutical industry, including at Novartis and GSK. At GSK, he was involved in the long-term strategy and lifecycle management planning for Shingrix, a leading shingles vaccine. He also managed the TUMS brand in the U.S., which is the top product in the antacid category.1 Nick began his career as an investment banking analyst with Deutsche Bank.1

In addition to his professional experience, Nick holds an MBA from the Tuck School of Business at Dartmouth College.2 His expertise spans across various facets of biopharma strategy and operations, making him a key player in advancing Senda Biosciences' mission of developing innovative medicines based on interspecies molecular interactions.